RxDoctor Payments Data

Ray Antonelli, MD

Family Medicine · Littleton, NCNPI 1285128348

Payments from drug & device makers

$1,625in general payments, 2019–2025

Across 68 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$613
  • Novo Nordisk$242
  • Mylan Specialty L.p.$153
  • Lilly USA, LLC$130
  • Dexcom, Inc.$120
  • Pfizer$68
  • plus $299 from 9 others

What the payments were for

  • Food & beverage$1,625100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,625 in reported general payments places this provider in the 75th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$7,169
Medicare patients
147
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$185,539
JardianceEmpagliflozin100$110,361
EliquisApixaban84$84,806
FarxigaDapagliflozin Propanediol84$71,168
XareltoRivaroxaban51$68,517
TrulicityDulaglutide29$42,769
LinzessLinaclotide27$31,935
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$29,599
MounjaroTirzepatide15$25,941
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$24,846
Victoza 3-PakLiraglutide17$23,491
RybelsusSemaglutide13$23,190
EntrestoSacubitril/Valsartan19$22,546
TradjentaLinagliptin18$20,665
JanuviaSitagliptin Phosphate18$17,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$242$208,729128 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$42$143,690139 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$613$108,238159 claims
PfizerEliquis$68$84,80684 claims
Lilly USA, LLCTrulicity, Mounjaro$130$68,71044 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$15$63,41392 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Littleton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →